HARP harpoontx.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Harpoon Therapeutics (HARP) automates the creation of oncology drugs through AI and robotics while simultaneously minimizing the environmental footprint of its laboratories. The current EV/EBITDA multiple of the business on GURU.Markets reflects the valuation trend, where the figure serves as the target level. Integration into a major pharmaceutical holding has provided the company with powerful resources for antibody development, eliminating the risks of price wars.

For Harpoon Therapeutics (HARP), which integrates bioplatforms into a global buyer's structure, assessing business value relative to operational cash flow is critical. This metric compares the total enterprise value (EV) with earnings before interest, taxes, depreciation, and amortization, eliminating the impact of debt load and accounting policies. By analyzing changes in the EV/EBITDA multiple, an investor determines the degree of asset overheating during the consolidation of R&D capacities.